19th Jan 2009 16:00
|
19 January 2009 |
ANGEL BIOTECHNOLOGY HOLDINGS PLC
("Angel" or "the Company")
Update on ReNeuron's clinical trial
Angel Biotechnology Holdings plc notes the announcement made by ReNeuron Group plc ("ReNeuron") earlier today stating that ReNeuron have received regulatory approval to commence a clinical trial with stem cell therapy for stroke.
As previously notified, Angel has been named as ReNeuron's manufacturing partner for nominated clinical trials. Angel would like to congratulate Reneuron on receiving this approval and the Company look forward to updating the market with further details when available.
For further information, please call:
|
Angel Biotechnology Holdings plc |
Tel: +44 (0) 131 445 6077 |
|
Gordon Sherriff - COO |
Tel: +44 (0) 7951 057016 |
|
Grant Thornton UK LLP, Nominated Adviser |
|
|
Philip Secrett, Colin Aaronson |
Tel+44 (0) 20 7383 5100 |
About Angel Biotechnology Holdings plc
Angel Biotechnology Holdings plc is a biomanufacturing company offering process development services and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines.
Angel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo, and Serologicals Inc.
Angel operates out of a sites, at Pentlands Science Park, near Edinburgh.
Angel was admitted to trading on AIM in November 2005.
Related Shares:
RENE.L